CD274 and breast cancer: TNBC is characterized by higher PD-L1 expression levels, with a median PD-L1 combined positive score (CPS) of 7.5, and 50% of cases exhibit a CPS of ≥10 compared to hormone receptor-positive (HR+) breast cancer.